This Article Full Text Full Text (PDF) All Versions of this Article: 36/11/2468    most recent 01.STR.0000185653.49740.c6v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Noor, J. I. Articles by Ikenoue, T. Search for Related Content PubMed PubMed Citation Articles by Noor, J. I. Articles by Ikenoue, T. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE Related Collections Animal models of human disease Acute Cerebral Infarction

(Stroke. 2005;36:2468.)
© 2005 American Heart Association, Inc.

Original Contributions

Short-Term Administration of a New Free Radical Scavenger, Edaravone, Is More Effective Than its Long-Term Administration for the Treatment of Neonatal Hypoxic–Ischemic Encephalopathy

Jesmin I. Noor, MD; Tomoaki Ikeda, MD; Kenichi Mishima, MD; Naoya Aoo, MD; Sumie Ohta, MD; Nobuaki Egashira, MD; Katsunori Iwasaki, MD; Michihiro Fujiwara, MD Tsuyomu Ikenoue, MD

From the Department of Obstetrics and Gynecology (J.I.N., T. Ikeda, T. Ikenoue), Faculty of Medicine, University of Miyazaki, Miyazaki, and the Department of Neuropharmacology (K.M., N.A., S.O., N.E., K.I., M.F.), Faculty of Pharmaceutical Sciences, Fukuoka University, Fukuoka, Japan.

Correspondence to Tsuyomu Ikenoue, MD, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. E-mail satomako{at}fc.miyazaki-med.ac.jp

Background and Purpose— Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one) is a new free radical scavenger that is used for the treatment of adult acute cerebral infarction in Japan. We examined the effect of edaravone on the optimal duration of treatment, the long-term effect on the brain, and the effect on learning and memory disability in a rat model of neonatal hypoxic–ischemic encephalopathy.

Methods— Seven-day-old Wistar rats were subjected to left common carotid artery ligation then 2 hours of hypoxic–ischemic insult or sham operation. Edaravone was administered intraperitoneally (9 mg/kg) after hypoxic–ischemic insult every 24 hours for 2, 5, or 10 consecutive days. The neuroprotective effect of edaravone was evaluated by behavioral test and histological analysis.

Results— Two-day treatment with edaravone significantly gave protection to the learning and memory capability, as well as morphological recovery compared with control rats. Five-day treatment showed morphological improvement but no behavioral improvement. In contrast, 10-day treatment did not show either morphological or behavior improvement.

Conclusions— These findings indicate that edaravone is a promising candidate as a treatment of choice for neonatal hypoxic–ischemic encephalopathy, when its use is limited to the acute phase after hypoxia–ischemia.

Key Words: edaravone • hypoxia–ischemia • learning impairment • Levine’s model • neonatal rat